• 1
    Beaugerie L, Carat F, Bouvier A, et al. Cohorte nationale CESAME (cancers et sur-risque associé aux maladies inflammatoires chroniques intestinales en France). données démographiques et médicales 2004–2005 pour 20919 patients 2006; 30: A154.
  • 2
    Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 2005; 54: 23741.
  • 3
    Louis E, Boverie J, Dewit O, Baert F, De Vos M, D’Haens G. Treatment of small bowel subocclusive Crohn’s disease with infliximab: an open pilot study. Acta Gastroenterol Belg 2007; 70: 159.
  • 4
    Oostenbrug LE, Van Dullemen HM, Te Meerman GJ, Jansen PL, Kleibeuker JH. Clinical outcome of Crohn’s disease according to the Vienna classification: disease location is a useful predictor of disease course. Eur J Gastroenterol Hepatol 2006; 18: 25561.
  • 5
    Vermeire S, Van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn’s disease – evidence for and against current therapies. Aliment Pharmacol Ther 2007; 25: 312.
  • 6
    Gelbmann CM, Mestermann S, Gross V, Kollinger M, Scholmerich J, Falk W. Strictures in Crohn’s disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin. Gut 1999; 45: 2107.
  • 7
    Graham MF. Pathogenesis of intestinal strictures in Crohn’s disease: an update. Inflamm Bowel Dis 1995; 1: 2207.
  • 8
    Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn’s disease strictures. Inflamm Bowel Dis 2004; 10: 5560.
  • 9
    Olaison G, Smedh K, Sjodahl R. Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33: 3315.
  • 10
    Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990; 99: 95663.
  • 11
    Hassan C, Zullo A, De Francesco V, et al. Systematic review: endoscopic dilatation in Crohn’s disease. Aliment Pharmacol Ther 2007; 26: 145764.
  • 12
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 13
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 2004; 126: 40213.
  • 14
    Treton X, Stefanescu C, Attar A, Alves A, Zappa M, Bouhnik Y. [Ileal stenosis]. Gastroenterol Clin Biol 2007; 31: 38792.
  • 15
    Bernstein CN, Greenberg H, Boult I, Chubey S, Leblanc C, Ryner L. A prospective comparison study of MRI versus small bowel follow-through in recurrent Crohn’s disease. Am J Gastroenterol 2005; 100: 2493502.
    Direct Link:
  • 16
    Schreyer AG, Golder S, Seitz J, Herfarth H. New diagnostic avenues in inflammatory bowel diseases. Capsule endoscopy, magnetic resonance imaging and virtual enteroscopy. Dig Dis 2003; 21: 12937.
  • 17
    Vasilopoulos S, Kugathasan S, Saeian K, et al. Intestinal strictures complicating initially successful Infliximab treatment for luminal Crohn’s disease. Am J Gastroenterol 2000; 2503: A315.
  • 18
    Toy LS, Scherl J, Kornbluth A, et al. Complete bowel obstruction following initial response to infliximab therapy for Crohn’s disease: a series of newly described complications. Gastroenterology 2000; 118: A569.
  • 19
    Lichtenstein GR, Olson A, Travers S, et al. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol 2006; 101: 10308.
    Direct Link:
  • 20
    Holtmann MH, Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn’s disease. Int J Colorectal Dis 2005; 20: 18.
  • 21
    Marrache F, Gornet JM, Pacault V, et al. Effet de l’infliximab au cours de la maladie de Crohn chez les patients ayant une sténose digestive. Gastroenterol Clin Biol 2005; 29: A188.
  • 22
    Geboes K, Dalle I. Influence of treatment on morphological features of mucosal inflammation. Gut 2002; 50(Suppl. 3): III3742.
  • 23
    D’Haens G. Mucosal healing in pediatric Crohn’s disease: the goal of medical treatment. Inflamm Bowel Dis 2004; 10: 47980.
  • 24
    Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn’s disease. Gastrointest Endosc 2006; 63: 43342.
  • 25
    Colombel JF, Bouhnik Y, Soulé JC, Lerebours E, groupe GETAID. Endoscopic healing of Crohn’s ileo-colitis with azathioprine. Gastroenterology 2003; 124: A196.
  • 26
    Soulé JC, Etieney I. L’imurel peut-il guérir la maladie deCrohn (MC)? Gastroenterol Clin Biol 2003; 27: A148.
  • 27
    Mantzaris JG, Petraki K, Chadio-Lordanides H, et al. Maintenance therapy with azathioprine is superior to budesonide in healing endoscopic lesions and improving histology in clinically quiescent Crohn's disease. Gastroenterology 2008;122:A81.
  • 28
    Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. The Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology 1992; 102: 164753.
  • 29
    Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn’s disease. Evolution on prednisolone. Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990; 98: 8118.
  • 30
    Hellers G, Cortot A, Jewell D, et al. Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. The IOIBD Budesonide Study Group. Gastroenterology 1999; 116: 294300.
  • 31
    Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007; 56: 4535.